… receptor blocker valsartan to standard therapy for heart failure. … Valsartan significantly
reduces the combined end point of … and symptoms in patients with heart failure, when added to …

… , the only ARB approved by the Food and Drug Administration (FDA) for use in heart failure
has been valsartan (Diovan, Novartis). This article reviews valsartan for use in heart failure. …

… of deaths due to heart failure increased steadily during the … Valsartan is an orally active
nonpeptide AII receptor antagonist … The use of valsartan in patients with heart failure, which is …

… — Valsartan added to background therapy for heart failure … may not be a critical marker of
the progression of heart failure. … -receptor blocker valsartan in chronic heart failure. N Engl J …

… We performed a post-hoc analysis of 5010 patients from the Valsartan Heart Failure Trial.
The … The risk of death due to progressive heart failure was 3.4-fold higher in the underweight …

… NE in heart failure patients are not … valsartan or placebo in the Valsartan Heart Failure Trial
(Val-HeFT) at baseline and 4, 12, and 24 months after randomization. The effects of valsartan …

… the US and the EU for the treatment of chronic heart failure (NYHA class II–IV) with … chronic
heart failure is commonly referred to as heart failure with reduced EF (HFrEF) or heart failure …

… administration study of valsartan in patients with congestive heart failure which showed that
… to assess the efficacy and safety of chronic treatment with valsartan in terms of its effect on …

… Our study shows that a further benefit may be achieved using the ARB valsartan in patients
with chronic HF on top of prescribed ACE inhibitor, amiodarone, and β-blocker therapies. …

… The Val-HeFT echocardiographic substudy of 5,010 patients with moderate heart failure
demonstrated that valsartan therapy taken with either ACEI or BB reversed LV remodeling. …